Answers are grounded in this paper and cite their sources.
Our study suggests that IFNβ-1b may trigger severe exacerbation in patients with the NMO spectrum. In INFβ-1b therapy, cases in NMO spectrum should be carefully excluded.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: